

Pazopanib Study VEG105192

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



No QoL benefit

#### Serious and disabling adverse effects



#### Other adjustments



Pazopanib Study VEG105192

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: First-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease

Experimental Arm: Pazopanib

Control Arm: Placebo (Crossover allowed)

